Stephens & Co. Reiterates Equal-Weight on Treace Medical Concepts, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst George Sellers has reiterated an Equal-Weight rating on Treace Medical Concepts (NASDAQ:TMCI) and maintained a $25 price target.
September 12, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Treace Medical Concepts' stock rating has been reiterated as Equal-Weight by Stephens & Co. with a maintained price target of $25.
The reiteration of the Equal-Weight rating and maintained price target by Stephens & Co. indicates a neutral outlook for TMCI. This is likely to neither significantly drive up nor depress the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100